Tadee Phacharaporn, Pattanawong Wiwat, Manwicha Apichart, Khaodang Pakasinee, Amornlerdpison Doungporn, Chansakaow Sunee, Tipduangta Pramote, Chukiatsiri Kridda, Tadee Pakpoom
Faculty of Animal Science and Technology, Maejo University, Chiang Mai 50290, Thailand.
Center of Excellence in Agricultural Innovation for Graduate Entrepreneur, Maejo University, Chiang Mai 50290, Thailand.
Biology (Basel). 2025 Mar 27;14(4):350. doi: 10.3390/biology14040350.
Mastitis is a major infectious disease that causes significant economic losses in the dairy industry. Current control programs primarily rely on antimicrobials, contributing to the growing concerns of the resistance situation and drug residues in milk. This study aimed to identify the bacterial pathogens responsible for subclinical/clinical bovine mastitis, assess their antimicrobial resistance profiles, and evaluate the antimicrobial effects of in treating mastitis through both in vitro and in vivo studies. A total of 138 bacterial isolates, representing 40 species, were identified from 100 milk samples collected from dairy cows under the Maejo Cooperative Group in Chiang Mai, Thailand, between May 2021 and February 2022. The most prevalent species was (10.87%), followed by (9.42%) and (7.97%). The highest resistance rates were observed for penicillin (65.21%), followed by streptomycin and lincomycin (61.59%). Nine isolates resisted all 18 antimicrobials tested. The average minimum inhibitory concentration (MIC) of against the identified pathogens ranged from 0.63 to 17.68 mg/mL, with the highest MIC observed against . In the animal experiment, treatment with a prototype of an intramammary infusion compound primarily formulated from significantly reduced the total bacterial count and California Mastitis Test (CMT) scores ( < 0.01). These results suggest that exhibits antimicrobial efficacy against various mastitis bacteria and could serve as a potential alternative treatment to control bovine mastitis in dairy cattle within the study region.
乳腺炎是一种主要的传染病，给乳制品行业造成了巨大的经济损失。当前的防控方案主要依赖抗菌药物，这加剧了人们对耐药情况以及牛奶中药物残留的担忧。本研究旨在鉴定引起亚临床/临床型牛乳腺炎的细菌病原体，评估它们的抗菌药物耐药谱，并通过体外和体内研究评估[具体物质]在治疗乳腺炎方面的抗菌效果。2021年5月至2022年2月期间，从泰国清迈湄周合作社集团的奶牛采集的100份牛奶样本中，共鉴定出138株细菌分离株，代表40个菌种。最常见的菌种是[具体菌种1]（10.87%），其次是[具体菌种2]（9.42%）和[具体菌种3]（7.97%）。观察到对青霉素的耐药率最高（65.21%），其次是链霉素和林可霉素（61.59%）。9株分离株对所有18种测试抗菌药物均耐药。[具体物质]对鉴定出的病原体的平均最低抑菌浓度（MIC）范围为0.63至17.68 mg/mL，对[具体菌种]观察到的MIC最高。在动物实验中，用主要由[具体物质]配制的乳房内输注化合物原型进行治疗，显著降低了总细菌数和加利福尼亚乳腺炎检测（CMT）评分（P < 0.01）。这些结果表明，[具体物质]对各种乳腺炎细菌具有抗菌效果，并且可以作为一种潜在的替代治疗方法，用于控制研究区域内奶牛的牛乳腺炎。
